16 September 2019 - Canada's only supplier, Merck, is now projecting BCG shortage will last until December 2020.

Canadians with bladder cancer will know this fall whether Health Canada will approve a second supplier of a life-saving drug that is being rationed as a worldwide shortage drags on.

BCG, or bacillus Calmette-Guérin, is an immunotherapy that involves injecting bacteria into the bladder through a catheter, triggering the immune system to attack the cancer.

Read CBC News article